Svas Biosana S.p.a. · MIL:SVS
Svas Biosana — Next Gems Conference 2022
18 slides from Svas Biosana's conference presentation, October 2022
Slide 1: Investor Presentation – Next Gems Conference October 2022
Investor Presentation Next Gems Conference – October 2022 Strictly Private and Confidential
Slide 2: Stock & Shareholders' Structure
Stock & Shareholders’ Structure Shareholders (1) Stock Performance (2) Exchange: Euronext Growth Milan Price (October 14th, 2022): € 8,35 Ticker: SVS - IM Market Cap: € 46.760.000 Perillo Umberto; Shares: 5.600.000 Average daily volume: 4.806 shares Free Float; 43,86% 32,00% IPO Price: € 12,50 IPO P
Slide 3: Group Overview – Svas Biosana At a Glance
Group Overview SVAS Biosana Group (“SVAS”, the “Company” or the “Group”) is an Italian leading player in the medical devices and disposables sector, acting Svas Biosana «At a Glance» both as a manufacturer and as a distributor. Key Financial Highlights The Group was founded in Southern Italy in 1972
Slide 4: Group Overview – Group Structure
Group Overview Group Structure Absolute majority of shares owned by Umberto Perillo Board of Directors Umberto Danila Antonia Svas Biosana Free Float Agrinvest S.r.l. Cofi Italia S.r.l. Belforte S.r.l. Filippo Maraniello Perillo Perillo S.p.A. Chairman 43,86% 6,35% 3,22% 0,93% 8,18% 5,46% 32,00% Umb
Slide 5: Geographical Presence and History
Group Overview Geographical Presence and History Warehouses and Offices ▪ Somma Vesuviana (NA) – 12.200 sqm: Chemical Microbiologic Division Division ❑ Site 1 (Via Trentola 7) Medical Devices in development Cosmetics Pharmaceutical ❑ Site 2 (Via Colle 104) Expertise Micro & Nanotechnology Bioenginee
Slide 6: Business Snapshot
Group Overview Legend Production & Sale Business Snapshot Distribution & Sale Company Activity Production Distribution Business Farmex €14,0m Medical €4,5m Svas €10,0m Mark Medical €16,0m Line(1) 31% 10% 22% 36% Custom Packs & Global Services Specialist Disposables Advanced Medical Incontinence Prod
Slide 7: H1 2022 Sales Breakdown
Group Overview H1 2022 Sales Breakdown By Activity By Geography By Customer Type Production Private 42% Customers Foreign ~ 30% Countries Italy H1 2022 36% Sales 64% Distribution 58% Public Customers ~ 70% First-class Suppliers Operating Company Operating Company National Public Hospitals Public Pur
Slide 8: Investment Highlights and Market Dynamics
Group Overview Investment Highlights and Market Dynamics 1. Rich and consolidated portfolio of products to satisfy chronic, 2. Qualified commercial structure and close relationship with medical operators medical and surgical healthcare needs generate additional value while creating high entry barrie
Slide 9: Financial Data – Key Financial Highlights
Financial Data Key Financial Highlights Millions of Euro EBITDA Net Revenues Millions of Euro 2018A 2019A 2020A 2021A H1 2021 H1 2022 Millions of Euro 12,0 € 10,6 13,5% 85,0 € 9,6 81,1 10,0 € 9,2 Net Revenue 69,1 73,6 76,0 81,1 38,6 43,8 8,3 13,0% 80,0 € YoY Δ 6,4% 3,4% 6,6% 13,6% 76,0 8,0 € 13,1% 7
Slide 10: Use of Proceeds
Use of Proceeds M&A and Investments Area M&A ▪ Identifying players for potential acquisitions and partnership to support external growth by Eastern Europe Western Europe Northern Italy strengthening the actual network, services and customer base in the neighboring area. ▪ Develop cost synergies ▪ De
Slide 11: Update on M&A Transaction
Update on M&A Transaction In June, Svas Biosana completed the acquisition of 75% of the capital of Bormia d.o.o. (the remaining 25% of shares are owned by the company itself). The group Bormia is active in the distribution of specialized medical devices in Slovenia, Croatia, Serbia and Bosnia. Throu
Slide 12: Annex – H1 Income Statement
Annex H1 Income Statement 30/06/2021 % 30/06/2022 % Delta % Revenues from sales and services 38.590.566 100% 43.843.886 100% 5.253.320 14% External costs 27.710.174 72% 33.165.592 76% 5.455.418 20% Added Value 10.880.392 28% 10.678.294 24% (202.098) -2% Cost of labor 5.560.999 14% 5.822.602 13% 261.
Slide 13: Annex – H1 Balance Sheet
Annex H1 Balance Sheet 31/12/2021 30/06/2022 Delta Net Intangible fixed assets 10.749.503 10.665.527 (83.976) Net Tangible Fixed Assets 25.639.396 25.892.450 253.054 Equity investments and other financial fixed assets 159.786 130.179 (29.607) Fixed Capital 36.548.685 36.688.156 139.471 Inventory 25.
Slide 14: Annex – 1H Consolidated Cash Flow Statement
Annex 1H Consolidated Cash Flow Statement 30/06/2021 30/06/2022 A) Cash Flows from Operating Activities 1) Profit (loss) for the year before income taxes, interest, dividends and capital gains / losses on disposal 3.436.615 3.150.731 2) Cash flow before changes in net working capital 6.033.896 5.983
Slide 15: Annex – Consolidated Income Statement
Annex Consolidated Income Statement 31/12/2020 % 31/12/2021 % Delta % Revenues from sales and services 76.044.082 100,0% 81.085.102 100,0% 5.041.020 6,6% External costs 56.310.557 74,0% 60.383.563 74,5% 4.073.006 7,2% Added Value 19.733.525 26,0% 20.701.539 25,5% 968.014 4,9% Cost of labor 11.385.91
Slide 16: Annex – Consolidated Balance Sheet
Annex Consolidated Balance Sheet 31/12/2020 31/12/2021 Delta Net intangible fixed assets 9.211.659 10.749.503 1.537.844 Net tangible fixed assets 25.793.903 25.639.396 -154.507 Equity investments and other financial fixed assets 130.179 159.786 29.607 Fixed capital 35.135.741 36.548.685 1.412.944 In
Slide 17: Annex – Consolidated Cash Flow Statement
Annex Consolidated Cash Flow Statement 31/12/2020 31/12/2021 A) Cash Flows from Operating Activities 1) Profit (loss) for the year before income taxes, interest, dividends and capital gains / losses on disposal 5.106.364 5.654.810 2) Cash flow before changes in net working capital 11.570.052 11.110.
Slide 18: Legal Disclaimer
Legal Disclaimer For the purposes of this disclaimer, this presentation (the “Presentation”) comprises the attached slides and any materials distributed at, or in connection with, the Presentation. The Presentation has been prepared by Svas Biosana S.p.A. (the “Company”) solely for information and d